Cell Therapy News

Cell Therapy News is an online resource dedicated to sharing the latest cell therapy, gene therapy, and regenerative medicine research.

Subscribe|Follow Us On

Matthew Larson Foundation Grant Helps Cancer Center Researcher Find New Ways to Treat Deadly Pediatric Brain Tumors

May 19, 2026

[University of Colorado Anschutz Cancer Center] Dr. Siddhartha Mitra recently received a three-year grant to develop chimeric antigen receptor (CAR) macrophages therapies to treat diffuse midline gliomas, a particularly deadly type of pediatric brain cancer.

Circadian Engineering of In Vivo CAR T Cell Therapy for Precision Oncology

May 15, 2026

[NPJ Precision Oncology] The authors discuss evidence that CD8⁺ T cell clocks, neuroendocrine oscillations, endothelial gatekeeping, and rhythmic tumor-microenvironment remodeling influence immune access, effector competence, exhaustion risk, and inflammatory toxicity.

First-in-Human Study of FLT3 CAR-T Cell Therapy for Relapsed Acute Myeloid Leukemia

May 15, 2026

[NPJ Precision Oncology] In this first-in-human open-label study, autologous FLT3 CAR-T cells were delivered to two patients with relapsed and refractory FLT3+ acute myeloid leukemia.

Europe’s First CAR T Cell Trial for Amyloidosis Opens

May 11, 2026

[University College London (UCL)] Three patients with light chain amyloidosis have been treated with CAR T cell therapy in the first European clinical trial testing the safety and efficacy of this immunotherapy in this patient group, led by UCL and UCLH researchers.

Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase I Trial of Lira-cel Ovarian Cancer CAR-T Therapy

May 11, 2026

[Anixa Biosciences, Inc. (PR Newswire)] Anixa Biosciences, Inc. announced updated positive survival observations from its ongoing Phase I clinical trial of liraltagene autoleucel, or lira-cel, a follicle-stimulating hormone receptor-targeted CAR-T therapy being developed for the treatment of recurrent ovarian cancer.

In Vivo Reprogramming of Cytotoxic Effector CD8 T Cells via Fractalkine-Conjugated mRNA-LNPs

May 11, 2026

[Science Immunology] Scientists demonstrated that fractalkine-conjugated mRNA lipid nanoparticles can specifically target and deliver mRNA to CX3CR1+ effector CD8 T cells in vitro and in vivo.

Ikaros Degradation by Mezigdomide Reduces T-Cell Dysfunction and Improves the Efficacy of Antimyeloma T-Cell Therapies

May 11, 2026

[Blood] Using bone marrow samples from multiple myeloma patients, scientists demonstrated a reduction in dysfunctional T cell populations expressing exhaustion markers such as TIGIT, upon treatment with Mezigdomide. They demonstrated the ability of Mezigdomide to enhance survival outcomes from anti-BCMA CAR-T therapy.

Antigen Spreading Mediates Heterogeneous Solid Tumor Eradication by DNA Demethylating Agent-Programmed CAR T Cells

May 11, 2026

[Science Advances] Investigators highlighted the potent antitumor activity of low-dose decitabine-primed CAR T cells (dCAR T) in solid tumor models, a benefit previously confirmed in hematologic malignancies. dCAR T cell infusion in immunocompetent mice led to elimination of mixed tumor masses containing, without the need for prior lymphodepletion.

Dual-Antigen-Targeting T Cell Immunotherapies in MM: Circumventing Tumor Heterogeneity and Preventing Antigen Escape

May 11, 2026

[Blood] Studies with limited numbers of patients have demonstrated that CAR T-cell products with specificity for >1 antigen are effective in advanced multiple myeloma; however, at this time, none of the dual-targeting CAR T-cell products have been shown to be clearly superior to targeting BCMA alone with ciltacabtagene autoleucel.

Enhancing CAR-T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF-Mediated Angiogenesis

May 11, 2026

[Advanced Science] Using multiple mouse models, scientists found that the impact of CAR-T cells on tumor growth is dose-dependent, capable of promoting, having no effect on, or inhibiting tumor growth. Combining CCL5-knockout CAR-T cells with the CCR5 inhibitor maraviroc significantly enhanced antitumor efficacy.

CAR T-Cells Targeting CD117 Effectively Eliminate Mast Cells in Preclinical Models of Advanced Systemic Mastocytosis

May 11, 2026

[Leukemia] Scientists assessed the therapeutic potential of anti-CD117 CAR T cells to target neoplastic mast cells (MCs) in systemic mastocytosis (SM). Anti-CD117-CAR T-cells lysed several SM-related human MC cell lines, MCs differentiated from SM patient-derived iPSCs, and neoplastic bone marrow cells.

RNA-Triggered Cell Killing with CRISPR-Cas12a2

May 6, 2026

[Nature] Researchers showed that Cas12a2, a recently discovered type V CRISPR nuclease, exhibits RNA-triggered DNA shredding15,16, and enables programmable and sequence-specific elimination of yeast and human cells expressing a target transcript.

Published since 2002, Cell Therapy News is our longest running online publication. Our editorial team curates the top publications, reviews, and news on in vivo gene therapy, cell therapy, and immunotherapy research. With over 15,000 subscribers and followers across our website, email newsletter, and Twitter feed, we are proud to facilitate the communication of cutting-edge cell therapy innovations.